Related Experiment Video
Updated: May 17, 2026
09:41
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Advancing pharmacometrics and systems pharmacology
Clinical Pharmacology and Therapeutics
|October 23, 2012
Summary
Pharmacometrics and systems pharmacology are key quantitative sciences in drug development. A new journal, CPT: Pharmacometrics & Systems Pharmacology, has been launched to advance these fields.
Area of Science:
- Quantitative sciences in drug development and experimental therapeutics.
- Pharmacometrics and systems pharmacology are central to clinical pharmacology.
Background:
- The American Society for Clinical Pharmacology and Therapeutics (ASCPT) recognizes the growing importance of quantitative sciences.
- ASCPT is collaborating with Nature Publishing Group and Clinical Pharmacology & Therapeutics.
Discussion:
- The establishment of CPT: Pharmacometrics & Systems Pharmacology aims to foster advancements in the field.
- This new journal will serve as a platform for disseminating research and shaping the discipline.
Key Insights:
- Pharmacometrics and systems pharmacology are critical for modern drug development.
- The new journal will provide a dedicated space for research in these quantitative sciences.
- Collaboration between major scientific societies and publishers underscores the significance of this initiative.
Outlook:
- CPT: Pharmacometrics & Systems Pharmacology is poised to become a leading resource for researchers and practitioners.
- The journal will play a vital role in advancing the fields of pharmacometrics and systems pharmacology.
- Future research in drug development will likely be heavily influenced by quantitative approaches.
Related Concept Videos
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:14Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A higher...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...